On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases

British Journal of Cancer

Volumn 88, Issue 3, 2003, Pages 424-431

  Bernsen, M R ^a,c   Hakansson L ^a   Gustafsson, B ^a   Krysander, L ^a   Rettrup, B ^b   Ruiter, D ^c   Hakansson A ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

B7.1; B7.2; Biochemotherapy; Melanoma; MHC II; Response

Indexed keywords

ALPHA2 INTERFERON; B7 ANTIGEN; BIOLOGICAL MARKER; CD86 ANTIGEN; CISPLATIN; DACARBAZINE; INTERFERON ALPHA2B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; MELANOMA; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR CELL; TUMOR REGRESSION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 0037428757     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600703     Document Type: Article

References (44)

1. Algarra I, Cabrera T, Garrido F (2000) The HLA crossroad in tumor immunology. Hum Immunol 61: 65-73
2. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S (1997) Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 94: 6886-6891
3. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S (1996) Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol 156: 3821-3827
4. Becker JC, Brabletz T, Czerny C, Termeer C, Bröcker (1993) Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int Immunol 5: 1501-1508
5. Blanck G (1999) HLA class II expression in human tumor lines. Microbes Infect 1: 913-918
6. Brocke P, Garbi N, Momburg F, Hammerling GJ (2002) HLA-DM, HLA-DO and tapasin: functional similarities and differences. Curr Opin Immunol 14: 22-29
7. Bröcker EB, Suter L, Sorg C (1984) HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 82: 244-247
8. Bröcker EB, Zwadlo G, Holzmann B, Macher E, Sorg C (1988) Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 41: 562-567
9. Castelli C, Rivoltini L, Mazzocchi A, Parmiani G (1997) T-cell recognition of melanoma antigens and its therapeutic applications. Int J Clin Lab Res 27: 103-110
10. Chen PW, Ullrich SE, Ananthaswamy HN (1994) Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes. J Leukoc Biol 56: 469-474
11. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77: 1303-1310
12. Coulie PG, Ikeda H, Baurain JF, Chiari R (1999) Antitumor immunity at work in a melanoma patient. Adv Cancer Res 76: 213-242
13. Davis ID (2000) An overview of cancer immunotherapy. Immunol Cell Biol 78: 179-195
14. Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G, Ting JP, Charron D, Alcaide-Loridan C (2001) Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J Immunol 167: 98-106
15. Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G (2001) Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ 12: 327-335
16. Greenfield EA, Nguyen KA, Kuchroo VK (1998) CD28/B7 costimulation: a review. Crit Rev Immunol 18: 389-418
17. Guerry D, Alexander MA, Elder DE, Herlyn MF (1987) Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma. J Immunol 139: 305-312
18. Håkansson A, Gustafsson B, Krysander L, Håkansson L (1996) Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 74: 670-676
19. Håkansson A, Gustafsson B, Krysander L, Håkansson L (1998) Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res 18: 33-39
20. Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Håkansson L (1999) On down-regulation of the immune response to metastatic malignant melanoma. Cancer Immunol Immunother 48: 253-262
21. Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Håkansson L (2001) Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer 85: 1871-1877
22. Hersey P, Jamal O (1990) Immunohistologlcal relation between DR antigen expression on melanoma cells and infiltration by CD8+ T cells. Pathology 22: 133-139
23. Kang S, Barnhill RL, Mihm MC, Sober AJ (1993) Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol 20: 126-129
24. Kosmaczewska A, Ciszak L, Bocko D, Frydecka I (2001) Expression and functional significance of CTLA-4, a negative regulator of T cell activation. Arch Immunol Ther Exp (Warsz) 49: 39-46
25. Legha SS (1997) The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 24: S24-S31
26. Marelli-Berg FM, Lechler RI (1999) Antigen presentation by parenchymal cells: a route to peripheral tolerance?. Immunol Rev 172: 297-314
27. Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkissoon J, Rosenberg SA, Parkinson DR (1992) HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 52: 6561-6566
28. Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G (1996) Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur J Immunol 26: 1851-1859
29. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W (2000) CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 14: 1156-1166
30. McGovern VJ (1975) Spontaneous regression of melanoma. Pathology 7: 91-99
31. Mihm MC, Clemente CG, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74: 43-47
32. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B (1997) Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 16: 2851-2860
33. Mukherji B, Chakraborty NG (1995) Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 7: 175-184
34. Nistico P, Tecce R, Giacomini P, Cavallari A, D'Agnano I, Fisher PB, Natali PG (1990) Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res 50: 7422-7429
35. Ostrand-Rosenberg S, Pulaski BA, Clements VK, Qi L, Pipeling MR, Hanyok LA (1999) Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev 170: 101-114
36. Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58: 1486-1493
37. Rees RC, Mian S (1999) Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol Immunother 48: 374-381
38. Robinson JH, Delvig AA (2002) Diversity in MHC class II antigen presentation. Immunology 105: 252-262
39. Ruiter DJ, Bhan AK, Harrist TJ, Sober AJ, Mihm Jr MC (1982) Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol 129: 2808-2815
40. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S (1991) MHC antigens in human melanomas. Semin Cancer Biol 2: 35-45
41. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S (1988) Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48: 1019-1025
42. van der Stoep N, Biesta P, Quinten E, van den Elsen PJ (2002) Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int J Cancer 97: 501-507
43. Yamshchikov G, Thompson L, Ross WG, Galavotti H, Aquila W, Deacon D, Caldwell J, Patterson JW, Hunt DF, Slingluff C-LJ (2001) Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin Cancer Res 7: 909s-916s
44. Zennadi R, Abdel-Wahab Z, Seigler HF, Darrow TL (2001) Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 ceils. Cell Imrnunol 210: 96-105